Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOVIGIST Phase II study of dovitinib in imatinib-refractory or intolerant GIST
2011-001725-24Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dovitinib in gastrointestinal stromal tumor (GIST), sponsored by Novartis. Primary endpoint: Disease control rate at 12 weeks. Started Sep 2011; status: completed.
02
Drugs
dovitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2011-001725-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001725-24.